- |||||||||| Pauci-Immune Crescentic Glomerulonephritis with Re-Initiation of Adalimumab for Crohn Disease () - Oct 23, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_5782;
For her CD, she was transitioned from adalimumab to vedolizumab (an oral monoclonal antibody with gut selective anti-inflammatory activity) due to concern that adalimumab contributed to her PICG...Discussion The TNFa inhibitors infliximab and etanercept have a rare association with PICG and in renal biopsy case series of patients with a history of IBD PICG has been reported. However, the association of adalimumab with ANCA negative PICG in this case is unique in the literature and may represent an under recognized etiology of glomerulonephritis in IBD.
- |||||||||| Clinical, Journal, Real-World Evidence: A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, DenmarkSpecial Reporting on:• VARSITY: A Double-Blind, Double-Dummy, Randomized Controlled Trial of Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis• Analyses of Data From the VISIBLE 1 and 2 Trials: Vedolizumab in Patients With Ulcerative Colitis or Crohn's Disease• Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib as an Induction Therapy in Adults With Moderately to Severely Active Ulcerative Colitis: Data From the U-ACHIEVE Study• Long-Term Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease: Final Results From the GEMINI LTS Study• Pediatric Crohn's Disease Adalimumab Level-Based Optimization Treatment (PAILOT) Randomized Controlled Trial• Maintenance Treatment With Mirikizumab, a P19-Directed IL-23 Antibody: 52-Week Results in Patients With Moderately to Severely Active Ulcerative Colitis• Real-World Effectiveness and Safety of Vedolizumab and Anti-TNF Therapy in Biologic-Naive Patients With Ulcerative Colitis or Crohn's Disease: Results From the EVOLVE Study• A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of a Targeted-Release Oral Cyclosporine Formulation in the Treatment of Mild to Moderate Ulcerative Colitis: Efficacy Results• Real-World Analyses of Patients With IBD Treated With VedolizumabPLUS Meeting Abstract SummariesWith Expert Commentary by:Edward V. Loftus Jr, MDProfessor of MedicineDivision of Gastroenterology and HepatologyMayo ClinicRochester, Minnesota. (Pubmed Central) - Oct 22, 2019
However, larger studies comparing the two agents are required. No abstract available
- |||||||||| Humira (adalimumab) / AbbVie
Enrollment closed, Trial completion date, Trial primary completion date: RIDD: Repurposing Anti-TNF for Treating Dupuytren's Disease (clinicaltrials.gov) - Oct 21, 2019 P2, N=209, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Sep 2020 | Trial primary completion date: Dec 2019 --> Apr 2020
- |||||||||| Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
TUMOR NECROSIS FACTOR BLOCKING AGENTS REDUCE RISK FOR ALZHEIMER’S DISEASE IN PATIENTS WITH CO-MORBID RHEUMATOID ARTHRITIS AND PSORIASIS. () - Oct 20, 2019 - Abstract #CTAD2019CTAD_291; Increased risk for AD also was found in patients ≥ 18 years with psoriasis (AOR = 1.37, 95% CI: (1.31-1.42), P-value <0.0001), ankylosing spondylitis (AOR = 1.57, 95% CI: (1.39-1.77), P-value <0.0001), inflammatory bowel disease (AOR = 2.46, 95% CI: (2.33-2.59) ), P-value <0.0001), ulcerative colitis (AOR = 1.82, 95% CI: (1.74-1.91), P-value <0.0001), and Crohn’s disease (AOR = 2.33 95% CI: (2.22-2.43), P-value <0.0001). The risk for AD in patients over 65 years with RA was reduced by treatment with etanercept (AOR = 0.34, 95% CI: (0.25-0.47), P-value <0.0001), adalimumab (AOR = 0.28, 95% CI: (0.19-0.39), P-value <0.0001), in iximab (AOR = 0.52, 95% CI: (0.39-0.69), P-value <0.0001) or methotrexate (AOR = 0.64, 95% CI: (0.61-0.68), P-value <0.0001).
- |||||||||| Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study (Hall B5) - Oct 19, 2019 - Abstract #ACRARHP2019ACR_4192;
We identified the initiators of one of the following biologic DMARDS: ustekinumab, secukinumab, ixekizumab, or TNFi, (i.e., adalimumab, etanercept, infliximab, certolizumab, golimumab). In this multi-database cohort of 123,383 PsO or PsA patients, ustekinumab initiators had a generally lower risk of hospitalized serious infection compared to TNFi, IL-17 therapy, and apremilast initiators.
- |||||||||| Stelara (ustekinumab) / J&J, Inflectra (infliximab biosimilar IV) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer, Humira (adalimumab) / Eisai, AbbVie
Humira, Stellara, Inflectra all sound lovely for a baby girl. Why aren’t there good boy names in #IBD world? @DCharabaty @IBDMD @IBD_Afzali @ibdgijami @ibddoctor @bottomline_ibd @IBDdoc @IBDdoc (Twitter) - Oct 18, 2019
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinical: Risk of uveitis in JIA - study 2294 JIA pts in the UK JIA registries finds that uveitis occured in 27/943 MTX, 16/1047, and only 1 of 304 adalimumab/infliximab Rx pts. No difference w/ MTX & etanercept, but much less with adalimumab https://t.co/rO13LznMmm (Twitter) - Oct 18, 2019
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Mortality, disability, and healthcare expenditure of patients with seropositive rheumatoid arthritis in Korea: A nationwide population-based study. (Pubmed Central) - Oct 17, 2019 Therefore, the rate of mortality and disability, as well as healthcare expenditure, are higher for patients with RA over the first 10 years of the disease onset, than the general population of Korea. The use of claim data has limited the quality of information and there is a limit to the observation period, and we expect the prospective national-wide multicenter cohort for longer period to overcome these limitations.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Clinical, Retrospective data, Journal: Clinical features and therapy of uveitis in childhood (Pubmed Central) - Oct 17, 2019 13 children with severe disease activity required biological therapy (adalimumab injection)...Orv Hetil. 2019; 160(34): 1335-1339.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Journal: Possible role of BMP-4 in the hyper-pigmentation of psoriatic plaques after anti-TNF-α treatment. (Pubmed Central) - Oct 17, 2019 Tyr, BMP-4 and melanin content were also evaluated in the psoriatic lesional skin of patients receiving adalimumab therapy, before and after 16 weeks of treatment...The present study confirmed the influence of the psoriatic pro-inflammatory network on melanogenesis, exerting an inhibitory effect mediated by TNF-α. Furthermore, the results regarding BMP-4 in the present study add another important element to the mechanism of psoriasis.
- |||||||||| Taltz (ixekizumab) / Eli Lilly, Humira (adalimumab) / Eisai, AbbVie
Journal: Ixekizumab superior to adalimumab for PsA. (Pubmed Central) - Oct 17, 2019 Furthermore, the results regarding BMP-4 in the present study add another important element to the mechanism of psoriasis. No abstract available
|